181 related articles for article (PubMed ID: 30009703)
1. Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions.
Hu C; Dong X
Curr Med Chem; 2019; 26(31):5811-5824. PubMed ID: 30009703
[TBL] [Abstract][Full Text] [Related]
2. Developing irreversible inhibitors of the protein kinase cysteinome.
Liu Q; Sabnis Y; Zhao Z; Zhang T; Buhrlage SJ; Jones LH; Gray NS
Chem Biol; 2013 Feb; 20(2):146-59. PubMed ID: 23438744
[TBL] [Abstract][Full Text] [Related]
3. The Cysteinome of Protein Kinases as a Target in Drug Development.
Chaikuad A; Koch P; Laufer SA; Knapp S
Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket.
Harling JD; Deakin AM; Campos S; Grimley R; Chaudry L; Nye C; Polyakova O; Bessant CM; Barton N; Somers D; Barrett J; Graves RH; Hanns L; Kerr WJ; Solari R
J Biol Chem; 2013 Sep; 288(39):28195-206. PubMed ID: 23935099
[TBL] [Abstract][Full Text] [Related]
5. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
[TBL] [Abstract][Full Text] [Related]
6. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
[TBL] [Abstract][Full Text] [Related]
7. Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy.
Das D; Hong J
Mini Rev Med Chem; 2020; 20(17):1732-1753. PubMed ID: 32400331
[TBL] [Abstract][Full Text] [Related]
8. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
Carmi C; Mor M; Petronini PG; Alfieri RR
Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
[TBL] [Abstract][Full Text] [Related]
9. Kinases inhibitors in lung cancer: From benchside to bedside.
Singh PK; Singh H; Silakari O
Biochim Biophys Acta; 2016 Aug; 1866(1):128-40. PubMed ID: 27393082
[TBL] [Abstract][Full Text] [Related]
10. Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches.
Zhang Y; Zhang D; Tian H; Jiao Y; Shi Z; Ran T; Liu H; Lu S; Xu A; Qiao X; Pan J; Yin L; Zhou W; Lu T; Chen Y
Mol Pharm; 2016 Sep; 13(9):3106-18. PubMed ID: 27483186
[TBL] [Abstract][Full Text] [Related]
11. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
[TBL] [Abstract][Full Text] [Related]
12. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
Yang Y; Shu YZ; Humphreys WG
Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335
[TBL] [Abstract][Full Text] [Related]
13. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S; Gurbani D; Du G; Everley RA; Browne CM; Chaikuad A; Tan L; Schröder M; Gondi S; Ficarro SB; Sim T; Kim ND; Berberich MJ; Knapp S; Marto JA; Westover KD; Sorger PK; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):818-829.e9. PubMed ID: 30982749
[TBL] [Abstract][Full Text] [Related]
14. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.
Liang Q; Chen Y; Yu K; Chen C; Zhang S; Wang A; Wang W; Wu H; Liu X; Wang B; Wang L; Hu Z; Wang W; Ren T; Zhang S; Liu Q; Yun CH; Liu J
Eur J Med Chem; 2017 May; 131():107-125. PubMed ID: 28315597
[TBL] [Abstract][Full Text] [Related]
15. Irreversible protein kinase inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2011; 18(20):2981-94. PubMed ID: 21651479
[TBL] [Abstract][Full Text] [Related]
16. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
[TBL] [Abstract][Full Text] [Related]
17. Anchor-based classification and type-C inhibitors for tyrosine kinases.
Hsu KC; Sung TY; Lin CT; Chiu YY; Hsu JT; Hung HC; Sun CM; Barve I; Chen WL; Huang WC; Huang CT; Chen CH; Yang JM
Sci Rep; 2015 Jun; 5():10938. PubMed ID: 26077136
[TBL] [Abstract][Full Text] [Related]
18. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Huang L; Jiang S; Shi Y
J Hematol Oncol; 2020 Oct; 13(1):143. PubMed ID: 33109256
[TBL] [Abstract][Full Text] [Related]
20. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.
Blair JA; Rauh D; Kung C; Yun CH; Fan QW; Rode H; Zhang C; Eck MJ; Weiss WA; Shokat KM
Nat Chem Biol; 2007 Apr; 3(4):229-38. PubMed ID: 17334377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
